Djouder, Nabil2024-02-082024-02-082015Mol Cell Oncol . 2015 Feb 3;2(4):e1001199.2372-3556http://hdl.handle.net/20.500.12105/17548Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide yet has limited therapeutic options. We recently demonstrated that inhibition of de novo nicotinamide adenine dinucleotide (NAD(+)) synthesis is responsible for DNA damage, thereby initiating hepatocarcinogenesis. We propose that boosting NAD(+) levels might be used as a prophylactic or therapeutic approach in HCC.engVoRhttp://creativecommons.org/licenses/by-nc-nd/4.0/Attribution-NonCommercial-NoDerivatives 4.0 Internacional2730849224e100119910.1080/23723556.2014.1001199Molecular & cellular oncologyopen access